Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
The present inventors investigated the effects of anti-IL-6 receptor antibodies on improving the condition of infarcted areas in myocardial infarction, and on suppressing left ventricular remodeling after myocardial infarction. As a result, the administration of anti-IL-6 receptor antibodies significantly suppressed the increase of MPO activity in the infarcted area and suppressed myocardial MCP-1 expression in both the infarcted area and the non-infarcted area. Furthermore, echocardiography and histological examinations revealed that cardiac hypertrophy is also suppressed.
1. A method for treating a myocardial infarction in a subject, the method comprising:
providing an interleukin-6 (IL-6) inhibitor, wherein the IL-6 inhibitor is an antibody that recognizes an IL-6 receptor; and
administering the antibody parenterally to a subject who has developed a myocardial infarction, thereby treating the myocardial infarction.
2. The method of claim 1 , wherein the antibody is a monoclonal antibody.
3. The method of claim 1 , wherein the antibody is an antibody against a human IL-6 receptor.
4. The method of claim 1 , wherein the antibody is a recombinant antibody.
5. The method of claim 1 , wherein the antibody is a chimeric antibody, humanized antibody, or human antibody.
6. The method of claim 1 , wherein the method further comprises monitoring the subject by echocardiography.
7. The method of claim 1 , wherein the antibody is administered by injection.
8. The method of claim 1 , wherein the antibody is administered by use of a catheter.
9. A method for suppressing left ventricular remodeling after a myocardial infarction in a subject, the method comprising:
providing an interleukin-6 (IL-6) inhibitor, wherein the IL-6 inhibitor is an antibody that recognizes an IL-6 receptor; and
administering the antibody parenterally to a subject who has developed a myocardial infarction and is suffering from or at risk of developing left ventricular remodeling, thereby suppressing left ventricular remodeling.
10. The method of claim 9 , wherein the antibody is a monoclonal antibody.
11. The method of claim 9 , wherein the antibody is an antibody against a human IL-6 receptor.
12. The method of claim 9 , wherein the antibody is a recombinant antibody.
13. The method of claim 9 , wherein the antibody is a chimeric antibody, humanized antibody, or human antibody.
14. The method of claim 9 , wherein the method further comprises monitoring the subject by echocardiography.
15. The method of claim 9 , wherein the antibody is administered by injection.
16. The method of claim 9 , wherein the antibody is administered by use of a catheter.